Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. (Nasdaq: CABA) is a clinical-stage biotechnology company pioneering engineered T cell therapies for autoimmune diseases. This page serves as the definitive source for official updates on clinical trials, research advancements, and corporate developments related to their innovative CAART and CARTA platforms.
Investors and researchers will find curated press releases detailing progress across multiple Phase 1/2 trials targeting conditions including lupus, myositis, and pemphigus vulgaris. Our collection features updates on therapeutic mechanisms that selectively eliminate pathogenic B cells while preserving healthy immune function.
The resource covers essential developments including trial design innovations, manufacturing process improvements, and strategic collaborations. All content is rigorously verified to ensure accuracy in reporting on this cutting-edge approach to autoimmune treatment.
Bookmark this page for streamlined access to Cabaletta Bio's latest milestones in developing potentially curative therapies. Check regularly for updates on clinical programs demonstrating the company's commitment to transforming autoimmune disease management.
Cabaletta Bio, Inc. (Nasdaq: CABA), a biotechnology firm specializing in engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in March 2021. The first is the Cowen & Co. 41st Annual Health Care Conference on March 3, where CEO Steven Nichtberger will engage in a cell therapy panel. The second is the H.C. Wainwright Global Life Sciences Conference on March 9, featuring a pre-recorded fireside chat. The discussion will be available on-demand post-conference on the company’s website for 90 days.
Cabaletta Bio, a clinical-stage biotechnology firm listed on Nasdaq as CABA, announced that its CEO, Steven Nichtberger, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 5:20 p.m. ET. A live webcast of the event will be available on the company's website and a recording will be accessible for 90 days post-event. Cabaletta is focused on engineered T cell therapies for B cell-mediated autoimmune diseases with its lead candidate, DSG3-CAART, currently in clinical trials.
Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), focuses on engineered T cell therapies for B cell-mediated autoimmune diseases. CEO Steven Nichtberger will present at two investor conferences on January 11, 2021. The presentations will be available via webcast on the company's website, starting at 6:00 a.m. and 7:00 a.m. ET respectively. The company's approach utilizes Chimeric AutoAntibody Receptor T cells, targeting specific autoantibody-producing B cells. Its leading candidate, DSG3-CAART, is in a phase 1 clinical trial for mucosal pemphigus vulgaris, with Fast Track Designation from the FDA.
Cabaletta Bio, Inc. (Nasdaq: CABA) achieved a significant milestone by infusing the first patient with its DSG3-CAART therapy during the DesCAARTes™ Phase 1 clinical trial. This trial aims to treat mucosal-dominant pemphigus vulgaris (mPV) and explores CAAR T cell technology for autoimmune diseases. DSG3-CAART could provide a more targeted and durable treatment option compared to current therapies that often induce broad immunosuppression. The trial will assess safety, tolerability, and early efficacy signs with an expected enrollment of 30 subjects across multiple sites in the U.S.
Cabaletta Bio, focused on engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in December 2020. Steven Nichtberger, M.D., the CEO, will partake in a pre-recorded chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 and a live discussion at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 3. The company’s pipeline includes DSG3-CAART, which targets mucosal pemphigus vulgaris and has received FDA Fast Track Designation. Webcast replays will be accessible for 90 days on their website.
Cabaletta Bio, Inc. (CABA) reported its Q3 2020 financial results, highlighting progress in its clinical programs. The company is actively enrolling patients in its Phase 1 trial for DSG3-CAART, aimed at treating mucosal pemphigus vulgaris, expecting to report acute safety data in the first half of 2021. Q3 R&D expenses rose to $5.7 million from $3.2 million in Q3 2019, and G&A expenses increased to $2.8 million from $1.8 million. As of September 30, 2020, cash and equivalents stood at $118.1 million, down from $136.2 million at year-end 2019, enough to fund operations through Q3 2022.
Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies for B cell-mediated autoimmune diseases, announced that CEO Steven Nichtberger will speak at three investor conferences in October 2020. The presentations include:
- Stifel 2020 Immunology and Inflammation Virtual Summit on October 1 at 3:00 p.m. ET.
- Jefferies Virtual Cell Therapy Summit on October 5 at 8:30 a.m. ET.
- Chardan 4th Annual Genetic Medicines Conference on October 6 at 11:30 a.m. ET.
Webcasts will be available on the company’s website.
Cabaletta Bio, a clinical-stage biotechnology company, announced that Dr. Steven Nichtberger will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET. A live webcast of the event will be available on their website, with a replay accessible for 90 days. The company is focused on engineered T cell therapies for B cell-mediated autoimmune diseases, leveraging their Cabaletta Approach to selectively eliminate specific B cells while preserving normal ones. Their lead candidate, DSG3-CAART, targets mucosal pemphigus vulgaris.
Cabaletta Bio, Inc. (CABA) announced promising in vivo preclinical data for its Chimeric AutoAntibody Receptor T cells targeting MuSK-associated myasthenia gravis. Presenting at AAN 2020, the data showed the T cells effectively recognized and eliminated B cells expressing anti-MuSK antibodies, with no harm to normal B cells. The study supports plans for Investigational New Drug (IND)-enabling studies in 2020, addressing a significant unmet need in MuSK MG treatment.
Cabaletta Bio, Inc. (CABA) announced its Q1 2020 financial results, highlighting a significant milestone with the FDA granting Fast Track Designation for its lead candidate, DSG3-CAART, aimed at treating mucosal pemphigus vulgaris (mPV). The Phase 1 DesCAARTes™ trial is ready to launch pending COVID-19 restrictions. R&D expenses were $4.6 million, while G&A expenses totaled $3.3 million. Cash reserves stood at $131 million, projected to support operations through Q3 2022.